title: [Diagnosis and correction of thrombohemorrhagic complications in cardiosurgical patients in the early postoperative period].
abstract: The methods of the prevention, diagnosis, and correction of hemostatic disorders are discussed in cardiosurgical patients. Prevention of hemorrhages requires hemostatic history data collection that allows identification of patients with concomitant hemophilia and those, taking antithrombotic drugs. The benefits of an extended study of blood coagulation disorders are shown in neonates and babies of the first year of life due to the physiological features of the hemostatic system and the pattern of heart disease. Algorithms are proposed for the diagnosis and treatment of hemorrhagic diathesis in the early postoperative period; a complex of minor signs of surgical hemorrhage is formulated, which makes it possible to timely perform rethoracotomy and to reduce blood transfusion. Efficiency evaluation and exclusion criteria for the use of recombinant factor VIIa are given. The efficiency of using the Russian drug tranexam versus epsilon-aminocapronic acid and aprotinin in the perioperative period was evaluated. The blood coagulative system was monitored in the treatment of disseminated intravascular coagulation in multiple organ dysfunction and sepsis, which promoted the timely use of recombinant human activated protein C and human antithrombin III. A diagnostic and treatment algorithm for replacement therapy of congenital heart disease concurrent with hemophilia A is given.
authors.forename: N N
authors.initials: NN
authors.lastname: Samsonova
authors.forename: L G
authors.initials: LG
authors.lastname: Klimovich
authors.forename: M B
authors.initials: MB
authors.lastname: Iarustovskiĭ
authors.forename: G V
authors.initials: GV
authors.lastname: Lobacheva
authors.forename: E F
authors.initials: EF
authors.lastname: Kozar
authors.forename: N V
authors.initials: NV
authors.lastname: Andreev
authors.forename: K E
authors.initials: KE
authors.lastname: Diasamidze
mesh_terms: D000328:Adult; D015119:Aminocaproic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007611:Aprotinin / Q000008:administration & dosage / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D006348:Cardiac Surgical Procedures; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use; D006330:Heart Defects, Congenital / Q000097:blood / Q000601:surgery; D006801:Humans; D007223:Infant; D019106:Postoperative Hemorrhage / Q000175:diagnosis / Q000188:drug therapy; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013927:Thrombosis / Q000175:diagnosis / Q000188:drug therapy; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D011994:Recombinant Proteins; D014148:Tranexamic Acid; D007611:Aprotinin; C103587:recombinant FVIIa; D015942:Factor VIIa; D015119:Aminocaproic Acid